SCHEMBL11072258

SCHEMBL11072258

N#C/C=C(\N)c1cccc(Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.52
RECQL P46063 1/20 0.49
KDM4E B2RXH2 2/20 0.47
HTT P42858 2/20 0.47
GRIN2B Q13224 2/20 0.42
MAPT P10636 4/20 0.42
GAA P10253 2/20 0.42
KMT2A Q03164 4/20 0.41
ALDH1A1 P00352 4/20 0.41
USP2 O75604 1/20 0.41
GABRA1 P14867 2/20 0.40
GABRG2 P18507 2/20 0.40
GABRB3 P28472 2/20 0.40
POLB P06746 2/20 0.40
PKM P14618 1/20 0.40
GABRB1 P18505 1/20 0.40
GABRB2 P47870 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11072261 1.00 PARP1 (0.52) PARP1RECQLKDM4EHTTGRIN2B
SCHEMBL11123552 1.00 PARP1 (0.52) PARP1RECQLKDM4EHTTGRIN2B
SCHEMBL7477836 0.80 PARP1 (0.44) PARP1KDM4EHTTGRIN2BMAPT
SCHEMBL7477831 0.80 PARP1 (0.44) PARP1KDM4EHTTGRIN2BMAPT
SCHEMBL29483451 0.79 MAPT (0.52) PARP1RECQLKDM4EHTTMAPT
SCHEMBL28724766 0.79 MAPT (0.52) PARP1RECQLKDM4EHTTMAPT
SCHEMBL11083594 0.79 PARP1 (0.52) PARP1RECQLGRIN2BMAPTKMT2A
SCHEMBL3958624 0.79 RECQL (0.49) RECQLGRIN2B
SCHEMBL21901287 0.79 PARP1 (0.52) PARP1RECQLKMT2AGABRA1GABRG2
SCHEMBL11085889 0.79 RECQL (0.62) PARP1RECQLGAAALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11078161-B2 Rock-inhibiting compound and uses thereof HITGEN INC. (CN) 2021-08-03 US disclosed
US-20200190035-A1 ROCK-INHIBITING COMPOUND AND USES THEREOF HITGEN INC. (CN) 2020-06-18 US disclosed
EP-0024776-B1 4-PHENYL AND 5-PHENYL-1,4,5,6-TETRAHYDROPYRIMIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES, AND PROCESS FOR PREPARING SAID DERIVATIVES SYNTEX (U.S.A.) INC. (US) 1984-12-27 EP disclosed
US-4322421-A 4-Phenyl-and 5-phenyl-1,4,5,6-tetrahydro-pyrimidine derivatives SYNTEX (U.S.A.) INC. (US) 1982-03-30 US disclosed
US-4261995-A DISORDERS OF CENTRAL NERVOUS SYSTEM AND CARDIOVASCULAR SYSTEM; HYPOTENSIVE SYNTEX (U.S.A.) INC. (US) 1981-04-14 US disclosed
EP-0024776-A1 4-Phenyl and 5-phenyl-1,4,5,6-tetrahydropyrimidine derivatives, pharmaceutical compositions containing said derivatives, and process for preparing said derivatives SYNTEX (U.S.A.) INC. (US) 1981-03-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11078161-B2 Rock-inhibiting compound and uses thereof ROCK1, ROCK2, RHOA PARP1 2453/4885RECQL 2998/4885KDM4E 1631/4885
US-20200190035-A1 ROCK-INHIBITING COMPOUND AND USES THEREOF ROCK1, ROCK2, RHOA PARP1 2453/4885RECQL 2998/4885KDM4E 1631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.